Global Next-Generation Breast Cancer Diagnostic and Screening Market Research Report 2023

The global Next-Generation Breast Cancer Diagnostic and Screening market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

North American market for Next-Generation Breast Cancer Diagnostic and Screening is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Next-Generation Breast Cancer Diagnostic and Screening is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The global market for Next-Generation Breast Cancer Diagnostic and Screening in Hospital-associated Labs is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The key global companies of Next-Generation Breast Cancer Diagnostic and Screening include Abbott Laboratories, Agendia, Agilent Technologies, Ambry Genetics, Biocept, Biotheranostics, Centogene, Danaher Corporation and EXACT Sciences Corporation, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Next-Generation Breast Cancer Diagnostic and Screening, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Next-Generation Breast Cancer Diagnostic and Screening.

The Next-Generation Breast Cancer Diagnostic and Screening market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Next-Generation Breast Cancer Diagnostic and Screening market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Next-Generation Breast Cancer Diagnostic and Screening companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Real-Time PCR (q-PCR)

1.2.3 Immunohistochemistry (IHC)

1.2.4 Next-Generation Sequencing (NGS)

1.2.5 Fluorescent In-Situ Hybridization (FISH)

1.3 Market by Application

1.3.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospital-associated Labs

1.3.3 Cancer Research Institutes

1.3.4 Diagnostic Centers

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Perspective (2018-2029)

2.2 Next-Generation Breast Cancer Diagnostic and Screening Growth Trends by Region

2.2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Region (2018-2023)

2.2.3 Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Region (2024-2029)

2.3 Next-Generation Breast Cancer Diagnostic and Screening Market Dynamics

2.3.1 Next-Generation Breast Cancer Diagnostic and Screening Industry Trends

2.3.2 Next-Generation Breast Cancer Diagnostic and Screening Market Drivers

2.3.3 Next-Generation Breast Cancer Diagnostic and Screening Market Challenges

2.3.4 Next-Generation Breast Cancer Diagnostic and Screening Market Restraints

3.1 Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Revenue

3.1.1 Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Revenue (2018-2023)

3.1.2 Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Players (2018-2023)

3.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Next-Generation Breast Cancer Diagnostic and Screening Revenue

3.4 Global Next-Generation Breast Cancer Diagnostic and Screening Market Concentration Ratio

3.4.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Next-Generation Breast Cancer Diagnostic and Screening Revenue in 2022

3.5 Next-Generation Breast Cancer Diagnostic and Screening Key Players Head office and Area Served

3.6 Key Players Next-Generation Breast Cancer Diagnostic and Screening Product Solution and Service

3.7 Date of Enter into Next-Generation Breast Cancer Diagnostic and Screening Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Type (2018-2023)

4.2 Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Type (2024-2029)

5.1 Global Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Application (2018-2023)

5.2 Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Application (2024-2029)

6.1 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size (2018-2029)

6.2 North America Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023)

6.4 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size (2018-2029)

7.2 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023)

7.4 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size (2018-2029)

8.2 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2018-2023)

8.4 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size (2018-2029)

9.2 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023)

9.4 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size (2018-2029)

10.2 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023)

10.4 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 Abbott Laboratories

11.1.1 Abbott Laboratories Company Detail

11.1.2 Abbott Laboratories Business Overview

11.1.3 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.1.4 Abbott Laboratories Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

11.1.5 Abbott Laboratories Recent Development

11.2 Agendia

11.2.1 Agendia Company Detail

11.2.2 Agendia Business Overview

11.2.3 Agendia Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.2.4 Agendia Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

11.2.5 Agendia Recent Development

11.3 Agilent Technologies

11.3.1 Agilent Technologies Company Detail

11.3.2 Agilent Technologies Business Overview

11.3.3 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.3.4 Agilent Technologies Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

11.3.5 Agilent Technologies Recent Development

11.4 Ambry Genetics

11.4.1 Ambry Genetics Company Detail

11.4.2 Ambry Genetics Business Overview

11.4.3 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.4.4 Ambry Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

11.4.5 Ambry Genetics Recent Development

11.5 Biocept

11.5.1 Biocept Company Detail

11.5.2 Biocept Business Overview

11.5.3 Biocept Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.5.4 Biocept Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

11.5.5 Biocept Recent Development

11.6 Biotheranostics

11.6.1 Biotheranostics Company Detail

11.6.2 Biotheranostics Business Overview

11.6.3 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.6.4 Biotheranostics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

11.6.5 Biotheranostics Recent Development

11.7 Centogene

11.7.1 Centogene Company Detail

11.7.2 Centogene Business Overview

11.7.3 Centogene Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.7.4 Centogene Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

11.7.5 Centogene Recent Development

11.8 Danaher Corporation

11.8.1 Danaher Corporation Company Detail

11.8.2 Danaher Corporation Business Overview

11.8.3 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.8.4 Danaher Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

11.8.5 Danaher Corporation Recent Development

11.9 EXACT Sciences Corporation

11.9.1 EXACT Sciences Corporation Company Detail

11.9.2 EXACT Sciences Corporation Business Overview

11.9.3 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.9.4 EXACT Sciences Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

11.9.5 EXACT Sciences Corporation Recent Development

11.10 Roche Holding AG

11.10.1 Roche Holding AG Company Detail

11.10.2 Roche Holding AG Business Overview

11.10.3 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.10.4 Roche Holding AG Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

11.10.5 Roche Holding AG Recent Development

11.11 Fulgent Genetics

11.11.1 Fulgent Genetics Company Detail

11.11.2 Fulgent Genetics Business Overview

11.11.3 Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.11.4 Fulgent Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

11.11.5 Fulgent Genetics Recent Development

11.12 Illumina

11.12.1 Illumina Company Detail

11.12.2 Illumina Business Overview

11.12.3 Illumina Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.12.4 Illumina Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

11.12.5 Illumina Recent Development

11.13 Invitae

11.13.1 Invitae Company Detail

11.13.2 Invitae Business Overview

11.13.3 Invitae Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.13.4 Invitae Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

11.13.5 Invitae Recent Development

11.14 Lucence Diagnostics Pte Ltd

11.14.1 Lucence Diagnostics Pte Ltd Company Detail

11.14.2 Lucence Diagnostics Pte Ltd Business Overview

11.14.3 Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.14.4 Lucence Diagnostics Pte Ltd Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

11.14.5 Lucence Diagnostics Pte Ltd Recent Development

11.15 Myriad Genetics

11.15.1 Myriad Genetics Company Detail

11.15.2 Myriad Genetics Business Overview

11.15.3 Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction

11.15.4 Myriad Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

11.15.5 Myriad Genetics Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Real-Time PCR (q-PCR)

    Table 3. Key Players of Immunohistochemistry (IHC)

    Table 4. Key Players of Next-Generation Sequencing (NGS)

    Table 5. Key Players of Fluorescent In-Situ Hybridization (FISH)

    Table 6. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 7. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 8. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2018-2023) & (US$ Million)

    Table 9. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region (2018-2023)

    Table 10. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 11. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region (2024-2029)

    Table 12. Next-Generation Breast Cancer Diagnostic and Screening Market Trends

    Table 13. Next-Generation Breast Cancer Diagnostic and Screening Market Drivers

    Table 14. Next-Generation Breast Cancer Diagnostic and Screening Market Challenges

    Table 15. Next-Generation Breast Cancer Diagnostic and Screening Market Restraints

    Table 16. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue by Players (2018-2023) & (US$ Million)

    Table 17. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Players (2018-2023)

    Table 18. Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next-Generation Breast Cancer Diagnostic and Screening as of 2022)

    Table 19. Ranking of Global Top Next-Generation Breast Cancer Diagnostic and Screening Companies by Revenue (US$ Million) in 2022

    Table 20. Global 5 Largest Players Market Share by Next-Generation Breast Cancer Diagnostic and Screening Revenue (CR5 and HHI) & (2018-2023)

    Table 21. Key Players Headquarters and Area Served

    Table 22. Key Players Next-Generation Breast Cancer Diagnostic and Screening Product Solution and Service

    Table 23. Date of Enter into Next-Generation Breast Cancer Diagnostic and Screening Market

    Table 24. Mergers & Acquisitions, Expansion Plans

    Table 25. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2018-2023) & (US$ Million)

    Table 26. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Type (2018-2023)

    Table 27. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 28. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Type (2024-2029)

    Table 29. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2018-2023) & (US$ Million)

    Table 30. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Application (2018-2023)

    Table 31. Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 32. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Application (2024-2029)

    Table 33. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 34. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023) & (US$ Million)

    Table 35. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2029) & (US$ Million)

    Table 36. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 37. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023) & (US$ Million)

    Table 38. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2029) & (US$ Million)

    Table 39. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 40. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2018-2023) & (US$ Million)

    Table 41. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2024-2029) & (US$ Million)

    Table 42. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 43. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023) & (US$ Million)

    Table 44. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2029) & (US$ Million)

    Table 45. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 46. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2018-2023) & (US$ Million)

    Table 47. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2024-2029) & (US$ Million)

    Table 48. Abbott Laboratories Company Detail

    Table 49. Abbott Laboratories Business Overview

    Table 50. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Product

    Table 51. Abbott Laboratories Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)

    Table 52. Abbott Laboratories Recent Development

    Table 53. Agendia Company Detail

    Table 54. Agendia Business Overview

    Table 55. Agendia Next-Generation Breast Cancer Diagnostic and Screening Product

    Table 56. Agendia Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)

    Table 57. Agendia Recent Development

    Table 58. Agilent Technologies Company Detail

    Table 59. Agilent Technologies Business Overview

    Table 60. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Product

    Table 61. Agilent Technologies Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)

    Table 62. Agilent Technologies Recent Development

    Table 63. Ambry Genetics Company Detail

    Table 64. Ambry Genetics Business Overview

    Table 65. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Product

    Table 66. Ambry Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)

    Table 67. Ambry Genetics Recent Development

    Table 68. Biocept Company Detail

    Table 69. Biocept Business Overview

    Table 70. Biocept Next-Generation Breast Cancer Diagnostic and Screening Product

    Table 71. Biocept Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)

    Table 72. Biocept Recent Development

    Table 73. Biotheranostics Company Detail

    Table 74. Biotheranostics Business Overview

    Table 75. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Product

    Table 76. Biotheranostics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)

    Table 77. Biotheranostics Recent Development

    Table 78. Centogene Company Detail

    Table 79. Centogene Business Overview

    Table 80. Centogene Next-Generation Breast Cancer Diagnostic and Screening Product

    Table 81. Centogene Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)

    Table 82. Centogene Recent Development

    Table 83. Danaher Corporation Company Detail

    Table 84. Danaher Corporation Business Overview

    Table 85. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Product

    Table 86. Danaher Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)

    Table 87. Danaher Corporation Recent Development

    Table 88. EXACT Sciences Corporation Company Detail

    Table 89. EXACT Sciences Corporation Business Overview

    Table 90. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Product

    Table 91. EXACT Sciences Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)

    Table 92. EXACT Sciences Corporation Recent Development

    Table 93. Roche Holding AG Company Detail

    Table 94. Roche Holding AG Business Overview

    Table 95. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Product

    Table 96. Roche Holding AG Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)

    Table 97. Roche Holding AG Recent Development

    Table 98. Fulgent Genetics Company Detail

    Table 99. Fulgent Genetics Business Overview

    Table 100. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Product

    Table 101. Fulgent Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)

    Table 102. Fulgent Genetics Recent Development

    Table 103. Illumina Company Detail

    Table 104. Illumina Business Overview

    Table 105. Illumina Next-Generation Breast Cancer Diagnostic and Screening Product

    Table 106. Illumina Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)

    Table 107. Illumina Recent Development

    Table 108. Invitae Company Detail

    Table 109. Invitae Business Overview

    Table 110. Invitae Next-Generation Breast Cancer Diagnostic and Screening Product

    Table 111. Invitae Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)

    Table 112. Invitae Recent Development

    Table 113. Lucence Diagnostics Pte Ltd Company Detail

    Table 114. Lucence Diagnostics Pte Ltd Business Overview

    Table 115. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Product

    Table 116. Lucence Diagnostics Pte Ltd Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)

    Table 117. Lucence Diagnostics Pte Ltd Recent Development

    Table 118. Myriad Genetics Company Detail

    Table 119. Myriad Genetics Business Overview

    Table 120. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Product

    Table 121. Myriad Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023) & (US$ Million)

    Table 122. Myriad Genetics Recent Development

    Table 123. Research Programs/Design for This Report

    Table 124. Key Data Information from Secondary Sources

    Table 125. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Type: 2022 VS 2029

    Figure 3. Real-Time PCR (q-PCR) Features

    Figure 4. Immunohistochemistry (IHC) Features

    Figure 5. Next-Generation Sequencing (NGS) Features

    Figure 6. Fluorescent In-Situ Hybridization (FISH) Features

    Figure 7. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 8. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application: 2022 VS 2029

    Figure 9. Hospital-associated Labs Case Studies

    Figure 10. Cancer Research Institutes Case Studies

    Figure 11. Diagnostic Centers Case Studies

    Figure 12. Next-Generation Breast Cancer Diagnostic and Screening Report Years Considered

    Figure 13. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 14. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 15. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region: 2022 VS 2029

    Figure 16. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Players in 2022

    Figure 17. Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next-Generation Breast Cancer Diagnostic and Screening as of 2022)

    Figure 18. The Top 10 and 5 Players Market Share by Next-Generation Breast Cancer Diagnostic and Screening Revenue in 2022

    Figure 19. North America Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 20. North America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2018-2029)

    Figure 21. United States Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 22. Canada Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 23. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 24. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2018-2029)

    Figure 25. Germany Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 26. France Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 27. U.K. Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. Italy Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. Russia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. Nordic Countries Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 31. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 32. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Share by Region (2018-2029)

    Figure 33. China Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. Japan Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. India Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. Australia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 39. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 40. Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2018-2029)

    Figure 41. Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 42. Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 43. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 44. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Share by Country (2018-2029)

    Figure 45. Turkey Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 46. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 47. Abbott Laboratories Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

    Figure 48. Agendia Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

    Figure 49. Agilent Technologies Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

    Figure 50. Ambry Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

    Figure 51. Biocept Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

    Figure 52. Biotheranostics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

    Figure 53. Centogene Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

    Figure 54. Danaher Corporation Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

    Figure 55. EXACT Sciences Corporation Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

    Figure 56. Roche Holding AG Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

    Figure 57. Fulgent Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

    Figure 58. Illumina Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

    Figure 59. Invitae Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

    Figure 60. Lucence Diagnostics Pte Ltd Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

    Figure 61. Myriad Genetics Revenue Growth Rate in Next-Generation Breast Cancer Diagnostic and Screening Business (2018-2023)

    Figure 62. Bottom-up and Top-down Approaches for This Report

    Figure 63. Data Triangulation

    Figure 64. Key Executives Interviewed